<SEC-DOCUMENT>0001104659-25-004628.txt : 20250121
<SEC-HEADER>0001104659-25-004628.hdr.sgml : 20250121
<ACCEPTANCE-DATETIME>20250121060107
ACCESSION NUMBER:		0001104659-25-004628
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250121

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BELITE BIO, INC
		CENTRAL INDEX KEY:			0001889109
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93970
		FILM NUMBER:		25540235

	BUSINESS ADDRESS:	
		STREET 1:		12750 HIGH BLUFF DRIVE SUITE 475
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-246-6240

	MAIL ADDRESS:	
		STREET 1:		12750 HIGH BLUFF DRIVE SUITE 475
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lin Bioscience International Ltd.
		CENTRAL INDEX KEY:			0001965750
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		36F., NO. 68, SEC. 5, ZHONGXIAO E. RD.,
		STREET 2:		XINYI DISTRICT
		CITY:			TAIPEI CITY
		STATE:			F5
		ZIP:			110
		BUSINESS PHONE:		886287805008

	MAIL ADDRESS:	
		STREET 1:		36F., NO. 68, SEC. 5, ZHONGXIAO E. RD.,
		STREET 2:		XINYI DISTRICT
		CITY:			TAIPEI CITY
		STATE:			F5
		ZIP:			110
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data:  -->
          <cik>0001965750</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Ordinary shares, par value US$0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001889109</issuerCik>
        <issuerName>Belite Bio, Inc</issuerName>
        <issuerCusip>07782B104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>12750 High Bluff Drive, Suite 475,</com:street1>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92130</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Lin Bioscience International Ltd.</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>17095263.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>17095263.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>17095263.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>53.7</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>(1)The percentage is calculated based upon an aggregate of 31,826,549 Ordinary Shares outstanding as of December 31, 2024, which is based on the information provided by the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Belite Bio, Inc</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>12750 High Bluff Drive, Suite 475, San Diego, CA 92130, United States of America</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13G is filed on behalf of Lin Bioscience International Ltd. ("Reporting Person")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Lin Bioscience International Ltd. is a company organized under the laws of the Cayman Islands.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>17,095,263</amountBeneficiallyOwned>
        <classPercent>53.7</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>17,095,263</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>17,095,263</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Lin Bioscience International Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>Yu-Hsin Lin</signature>
        <title>Yu-Hsin Lin/Director</title>
        <date>01/21/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
